# 🎉 Join the Celebration: 8th Anniversary Bonus for Investors – Through Aug 31! | Sen-Jam Pharmaceutical

- Canonical URL: https://wefunder.com/feed/184407
- Entity ID: wefunder:feed_item:184407
- Published at: 2025-08-05 15:48:32 UTC
- Updated at: 2025-08-05 15:53:35 UTC

## Author
Jim Iversen

## Subject
Sen-Jam Pharmaceutical

## Content
Dear Sen-Jam Community,As shared in last week’s “Catalyzing the Next Milestone” webinar, Sen-Jam is ready to deploy capital into several high-value initiatives designed to accelerate our growth and maximize investor returns.This August marks 8 years since Sen-Jam Pharmaceutical was founded, and we’re celebrating in a big way:Limited-Time Investor Bonus: +50% “Special Bonus” on Fractional Royalty Rights (FRR) and Bonus Shares – available only through August 31, 2025.Even better, this special bonus is retroactive for everyone who has already invested in our current campaign.What You GetTranche IV Fractional Royalty Rights of 1% of SJP-001 Patent Portfolio for 1st $1M raise$1,000 - Tranche IV Fractional Royalty Right (FRR) Terms (e.g., Special Bonus - 150% FRR)$5,000 – $1k Perk + 30% FRR Kicker (e.g., Special Bonus – 195% FRR)$10,000 - $1k Perk + 50% FRR Kicker (e.g., Special Bonus – 225% FRR)$25,000 - $10k Perk + 10% Bonus Shares (e.g., Special Bonus – 15% Bonus Shares & 225% FRR)$50,000 - $10k Perk + 12 % Bonus Shares (e.g., Special Bonus – 18% Bonus Shares & 225% FRR)$100,000 - $10k Perk + 14% Bonus Shares (e.g., Special Bonus – 21% Bonus Shares & 225% FRR)That’s right, for the month of August, a $10,000 investment will get you 2.25 times the number of Fractional Royalty Rights.Why Invest Now - So Many Reasons:Sen-Jam Pharmaceutical was recently highlighted in the Oppenheimer Longevity Report Catch the Next Wave – Longevity, on pages 28, 41, and 45, and we were called out in their 20 min- "Must Listen" podcast at 15:48 mins.SJP-002C clinical trial results confirm our therapeutic being the broadest spectrum oral anti-inflammatory with the least side effects worldwide, confirming our entire PAIR technology platform. Also, KVK Tech’s 6-month accelerated stability results have passed, and the CMC package for the FDA NDA submission is ready. Completing this milestone increases our likelihood of success as well as our valuation.SJP-001 clinical trial is targeted to be completed at the end of 2025, and KVK Tech expects to initiate manufacturing of submission batches in December.SJP-005 study results from the National Institute of Drug Abuse (NIDA) show promise, with NIDA advancing additional studies. Earlier this year, Vertex Pharmaceutical received FDA approval for a non-opioid pain reliever (1st novel non-opioid pain reliever approved in 25 years). Subsequently, Lilly announces the acquisition of SiteOneTherapeutics for $1B to expand its pain pipeline.Destum Partners continues to advance discussions with potential Strategic Partners for out-licensing, co-development, or M&A for SJP-001 & SJP-002C.Let’s celebrate together by investing now or contact us if you want to learn about our philanthropic/Donor-Advised-Funds offering our Healthspan Catalyst Fund.Thanks for your continued support!Jim